CLINICAL USE


Hypotension Cardiac arrest (sympathomimetic)

DOSE IN NORMAL RENAL FUNCTION

(Doses expressed as noradrenaline acid tartrate)Acute hypotension: 80 mcg/mL solution, initially 0.16–0.33 mL/minute; adjust according to responseCardiac arrest: 200 mcg/mL solution, 0.5–0.75 mL

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :337.3
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :~50
  • %Excreted unchanged in urine &nbsp &nbsp : ~16
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.09–0.4
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1 minute/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAdrenergic neurone blockers: antagonise hypotensive effect
  • Antidepressants: tricyclics may cause hypertension and arrhythmias; MAOIs and moclobemide may cause hypertensive crisis
  • Beta-blockers: can cause severe hypertension
  • Clonidine: possibly increased risk of hypertension
  • Dopaminergics: effects possibly increased by entacapone; avoid concomitant use with rasagiline
  • Sympathomimetics: effects possibly enhanced by dopexamine

    ADMINISTRATION

    Reconstition

    Route

    IV

    Rate of Administration

    According to response

    Comments

    Preferably give centrally (low pH) Dilute 1–4 mg in 100 mL glucose 5% Can be given undiluted

    OTHER INFORMATION

    Do not mix with alkaline drugs/solutions The pharmacokinetics of noradrenaline are not significantly affected by renal or hepatic diseasenoradrenaline acid tartrate (norepinephrine bitartrate).